Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxis

Acta Ophthalmol. 2011 Mar;89(2):e206-7. doi: 10.1111/j.1755-3768.2009.01773.x.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Intramural

MeSH terms

  • Aged
  • Aged, 80 and over
  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / immunology*
  • Animals
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / immunology*
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neutralizing / blood*
  • Bevacizumab
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Intravitreal Injections
  • Macular Degeneration / drug therapy
  • Macular Degeneration / immunology
  • Male
  • Prospective Studies
  • Rabbits
  • Tachyphylaxis / immunology*
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neutralizing
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab